Han Biomedical (ROCO:6999) EBIT: NT$29.4 Mil (TTM As of Dec. 2025)


ROCO:6999 Han Biomedical Inc ROCO:6999
25 GF Score
Price NT$30.00
! 1 Warning Sign
View Full Analysis

What is Han Biomedical EBIT?

Han Biomedical ROCO:6999 +0.17% 25 EBIT is NT$29.4 Mil as of Dec. 2025. GuruFocus rates ROCO:6999 with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Han Biomedical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$16.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$29.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Han Biomedical's annualized ROC % for the quarter that ended in Dec. 2025 was 20.57%. Han Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 35.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Han Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 5.80%.

Han Biomedical  (ROCO:6999) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Han Biomedical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=26.342 * ( 1 - 22.17% )/( (91.761 + 107.577)/ 2 )
=20.5019786/99.669
=20.57 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=309.255 - 40.274 - ( 177.22 - max(0, 45.531 - 242.915+177.22))
=91.761

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=303.067 - 23.806 - ( 171.684 - max(0, 29.041 - 240.406+171.684))
=107.577

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Han Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=32.95/( ( (64.049 + max(21.605, 0)) + (59.873 + max(39.973, 0)) )/ 2 )
=32.95/( ( 85.654 + 99.846 )/ 2 )
=32.95/92.75
=35.53 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(30.623 + 30.037 + 1.515) - (40.274 + 0 + 0.296)
=21.605

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.816 + 29.361 + 1.823) - (23.806 + 0 + 0.221)
=39.973

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Han Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=29.401/507.272
=5.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Han Biomedical EBIT Related Terms

Han Biomedical EBIT Historical Data

* Premium members only.

The historical data trend for Han Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Han Biomedical EBIT Chart

Han Biomedical Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
16.70 24.42 27.27 30.94 29.40

Han Biomedical Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 18.02 13.16 17.78 12.93 16.48

ROCO:6999 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Han Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Han Biomedical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Han Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Han Biomedical's EV-to-EBIT falls into.


ROCO:6999
25GF Score
Han Biomedical Inc ROCO:6999
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Han Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$29.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$29.4 Mil mean?
Han Biomedical (ROCO:6999) has a EBIT of NT$29.4 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Han Biomedical.
Is Han Biomedical's EBIT too high?
Han Biomedical's current EBIT is NT$29.4 Mil. Overall, Han Biomedical has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Han Biomedical's EBIT compare to VRTX and REGN?
Han Biomedical's EBIT of NT$29.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Han Biomedical. Han Biomedical's current EBIT is NT$29.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Han Biomedical stock overvalued right now?
Han Biomedical (ROCO:6999) has a current EBIT of NT$29.4 Mil. The current EBIT is NT$29.4 Mil. Han Biomedical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Han Biomedical (ROCO:6999), the current EBIT is NT$29.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Han Biomedical Business Description

Address Xintai 5th Road, 15F-11, No.99, Sec.1, Xizhi District, New Taipei City, TWN
Han Biomedical Inc operates as a bio-material technology platform for the tissue repair market.
25GF Score

Get the complete analysis for ROCO:6999

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.00
Price